Objective: This study was performed to assess the clinical feasibility and surgical outcomes of video-assisted mediastinoscopic lymphadenectomy in the treatment of resectable lung cancer. Methods: Between July 2004 and December 2009, we retrospectively analyzed 108 consecutive video-assisted mediastinoscopic lymphadenectomies in lung cancer patients from a prospectively collected database. Ninety-seven (89.8%) patients underwent combined operation during the same anesthesia and six (5.3%) patients underwent a staged operation for the resection of lung cancer and systematic lymphadenectomy. We reviewed the indication and duration of video-assisted mediastinoscopic lymphadenectomy, its complication, combined or staged operation type, the number of dissected lymph nodes and nodal stations, and pathologic staging of the mediastinal node. Results: Mean operative time of video-assisted mediastinoscopic lymphadenectomy was 39.8 AE 12.3 min (range of 14-85 min). Mean number of resected lymph nodes was 16.0 AE 7.7 (range of 3-37). In video-assisted mediastinoscopic lymphadenectomy, the rates of lymph node dissection of stations 4R, 4L, and 7 were 71.3%, 88.0%, and 100%, respectively, whereas the rates of dissection of lymph nodes in station 2R and 2L were only 22.2% and 17.6%, respectively. There was no operative mortality. We identified five complications of recurrent nerve palsy. Conclusions: Video-assisted mediastinoscopic lymphadenectomy is a clinically feasible procedure with acceptable complication rate and provides more accurate staging of mediastinal node in lung cancer patients. It may be also an excellent supplementary technique used for complete mediastinal node dissection at minimal invasive surgery for cancer resection, especially with left-sided video-assisted thoracoscopic lobectomy. #
Introduction
Since standard mediastinoscopy was first introduced in 1959 by Carlens [1] , its method has been little modified. Linder and Dahan developed a two-bladed expandable videomediastinoscope in 1992 [2] , which allowed bimanual manipulation, better exposure, and the development of new surgical techniques, such as video-assisted mediastinoscopic lymphadenectomy (VAMLA). Hürtgen reported the first experiences of VAMLA in 2002, showing its technical feasibility, safety, and accuracy of radical mediastinal lymph node dissection [2] .
Accurate pretherapeutic staging of mediastinal lymph nodes in lung cancer patients is essential to determine the choices of treatment modalities and prognosis. Computed tomography (CT) scan plays a basic role in lung cancer staging but it is not reliable for mediastinal lymph node staging. [2, 3] Positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) is superior to CT scan for mediastinal lymph node staging. However, the positive predictive value and the specificity of PET scan are lower than those of mediastinoscopy because FDG is also taken up by inflammatory processes [3] . PET-positive mediastinal findings should be histologically or cytologically confirmed [3] . Transbronchial needle aspiration, ultrasound-guided bronchoscopy fine-needle aspiration (EBUS-FNA), and esophagoscopy fine-needle aspiration (EUS-FNA) are new techniques of providing cyto-histological diagnosis and are minimally invasive methods. However, their low negative predictive value often requires an invasive surgical staging in spite of the negative result of fine needle aspiration [3] .
Mediastinoscopy is an invasive method requiring general anesthesia, but it has the highest sensitivity and specificity for staging of mediastinal lymph node in lung cancer patients [4] . The sensitivity of mediastinoscopy is mostly influenced by the amount of resected lymph node tissue and the number www.elsevier.com/locate/ejcts European Journal of Cardio-thoracic Surgery 40 (2011) [1483] [1484] [1485] [1486] of investigated lymph node stations [2] . In contrast with standard mediastinoscopy, the number of lymph nodes resected with VAMLA increased nearly twofold [4] . Its accuracy in mediastinal nodal staging in lung cancer patients is nearly equal to open lymphadenectomy [5] .
In this study, we analyzed our experience of 108 consecutive VAMLAs in lung cancer patients with focus on its safety, complication, clinical feasibility, radicality, and accuracy of nodal staging in the treatment of resectable lung cancer.
Materials and method

Instruments and technique
We have used a Linder-Dahan videomediastinoscope (Richard Wolf, Knittlingen, Germany) instead of a conventional mediastinoscope since July 2004, which is a prerequisite for VAMLA. In contrast with a conventional mediastinoscope, the Linder-Dahan videomediastinoscope consists of an expandable two-bladed speculum, therefore allowing optimal exposure of mediastinal structures and bimanual surgery with the dissecting aspirator, biopsy forceps, grasping forceps, dissectors, clip appliers, and scissors.
The initial surgical steps of VAMLA, prior to the introduction of the mediastinoscope into the upper mediastinum, did not differ from those of standard mediastinoscopy. General anesthesia and tracheal intubation with a single-lumened endotracheal tube were employed. The patient was positioned supine with a roll under the shoulders to provide extension of the neck. After the paratracheal fascia opening and finger blunt dissection along the trachea, the videomediastinoscope was introduced and positioned in the pretracheal space. The inferior valve of the videomediastinoscope was opened and blocked to create a wide operative field. During bimanual preparation, the videomediastinoscope was maintained fixed by an assistant. Using the dissecting aspirator, further dissection was carried out under direct visual control. Endoscopic graspers, scissors, and clip appliers were also used when indicated. The trachea, superior vena cava, azygos vein, right main pulmonary artery, and left recurrent laryngeal nerve were well identified. Progression behind the right main pulmonary artery allowed exploration of both main bronchi and subcarinal area. Stations 2, 4, and 7 nodes were easily accessible for en bloc resection or biopsy. Wherever possible, en bloc resection of lymph nodes and fatty tissue was usually performed in stations 2 and 4 on the same side of lung cancer as well as in station 7. On the other hand, systematic sampling was usually performed in stations 2 and 4 on the opposite side of tumor. Further systematic biopsies of all the accessible nodes were also carried out. During surgery, the surgeon indicated the station of resected lymph node. Specimens were then sent to the laboratory for frozen sections. If there was suspicious vascular structure, it was confirmed by needle aspiration before biopsy or resection. For controlling minor hemorrhages, coagulation, gauze compression, or clips were used. Drainage was not employed in any patients. In case of simultaneous operation for cancer resection, a single-lumened endotracheal tube was changed to a double-lumened tube and the patient was turned in full lateral position as for a standard posterolateral thoracotomy.
Patients
Since 2004, VAMLA was performed mostly in consecutive, operable, left-sided lung cancer patients with clinical N0, N1, or single station N2, and rarely in selected potentially operable right-sided lung cancer patients with clinically suspicious N3. It is well known that the left side is more difficult, even at thoracotomy, to explore mediastinal lymph nodes, compared with the right side. Therefore, we planned to perform VAMLA combined with video-assisted thoracoscopic (VATS) lobectomy in left-sided resectable lung cancer in 2004. VAMLA was usually not performed for right-sided lung cancer because we considered that the radicality of mediastinal lymph node dissection with right-sided VATS lobectomy might be equal to that with open lymphadenectomy.
In prospective data collection, all consecutive videomediastinoscopies in lung cancer patients had been enrolled at the Asan Medical Center in Seoul Korea between June 2004 and December 2009. A total of 114 videomediastinoscopies was performed by single surgeon in potentially operable lung cancer patients. Informed written consent of each patient was obtained. All videomediastinoscopies were carried out for the mediastinal staging or therapeutic lymphadenectomy of known lung cancer: of these 93 procedures had been planned for systematic mediastinal dissection in resectable lung cancer patients with clinical N0 or N1, and 21 procedures for identifying the mediastinal node involvement in potentially operable lung cancer patients with clinically suspicious N3. In these 114 videomediastinoscopies, systematic mediastinal lymph node dissection (VAMLA) was performed in 108 patients and diagnostic mediastinal node biopsy in six patients. The latter six cases were not considered the true VAMLAs; therefore, those were excluded from this study. A total of 108 VAMLAs were analyzed in this study.
We reviewed the patient's data with indication, duration of VAMLA, VAMLA-related complication, combined or staged operation type, the number of lymph nodes and nodal stations resected by VAMLA, and pathologic staging of mediastinal node.
Results
Among 108 lung cancer patients who underwent VAMLA between July 2004 and December 2009, there were 70 males and 38 females with mean age of 62.2 AE 10.1 years (range of 35-84 years). Adenocarcinoma (n = 68, 63.0%) and squamous cell carcinoma (n = 28, 25.9%) were common histologies of lung cancer in this study. The site of tumor was mostly the left side (n = 99, 91.7%). Patient characteristics are summarized in Table 1 .
Mean operative time of VAMLA (excluding the time for combined procedures) was 39.8 AE 12.3 min (range of 14-85 min): mean number of resected lymph nodes using videoassisted mediastinoscopy was 16.0 AE 7.7 (range of 3-37): Mean number of removed nodal stations was 3.5 AE 1.1 (range of 2-6). Operative results are detailed in Table 2 . Lymph node dissection of stations 4R, 4L, and 7 was gained in 77 (71.3%), 95 (88.0%), and 108 (100%) patients, respectively, whereas resection of lymph nodes in stations 2R and 2L was performed in only 24 (22.2%) and 19 (17.6%) patients, respectively. After VAMLA, clinical nodal staging based on CT scan was the same as pathologic staging in 79 patients, and was down-staged in 19 patients, whereas the clinical staging of 10 patients was up-staged. The eight patients with clinically inoperable lung cancer with N3, based on CT scan, were all down-staged to pathologic staging of N0 or N2 in six and two patients, respectively (Fig. 1) .
Combined operations for resection of lung cancer were performed in 97 patients (89.8%) during the same anesthesia, consisting of 90 VATS lobectomies, five VATS segmentectomies, one VATS wedge resection, and one open lobectomy. The only VATS wedge resection was performed in the patient with poor pulmonary function. For variable reasons, staged anatomic resection of lung cancer was performed in six patients, consisting of four VATS lobectomies, one VATS segmentectomy, and one open lobectomy. Four patients refused the staged operation for cancer resection and one patient with N3 node involvement was referred to the oncologist for chemotherapy. During combined or staged operation, there were no residual lymph nodes found in stations 2R, 4R, and 7 in right-sided lung cancer, and in stations 4L and 7 in left-sided lung cancer.
After combined or staged procedures, the final pathologic nodal staging agreed with that based on VAMLA, except for only one patient (Fig. 1) . The nodal staging of the patient was up-staged from N0 to N1 (interlobar node); hence, there were no false negative results.
There was no operative mortality. Five VAMLA-related complications were observed: all were recurrent laryngeal nerve palsies. There were no other complications, such as major bleeding, injury to tracheobronchial tree, esophageal injury, and chylothorax.
Discussion
The Linder-Dahan videomediastinoscope, consisting of an expandable two-bladed speculum, is a prerequisite for VAMLA. It allows a surgeon to perform bimanual preparation and delicate dissection with some advantages of improved operative field and training of surgeons [2, [4] [5] [6] .
In treating lung cancer patients, accurate staging of mediastinal lymph nodes is essential for selecting optimal stage-oriented therapy, determining outcome, and comparison of studies [2] [3] [4] . CT scan plays a basic role in lung cancer staging. For the nodal staging, however, it is well known that its sensitivity and specificity are low [2, 3] . The PET scan is better than the CT scan for the staging of mediastinal node, but it is unreliable [2, 3, 6] . PET-positive mediastinal findings should be cytologically or histologically confirmed [3] . EBUS-FNA and EUS-FNA are new methods of providing cytohistological diagnosis with minimal invasiveness [3] . Current studies demonstrated that the combined approach of EBUS- VAMLA, video-assisted mediastinoscopic lymphadenectomy; VATS, videoassisted thoracoscopic surgery. FNA and EUS-FNA, a recently introduced method in the mediastinal staging of lung cancer, provided higher diagnostic yields compared with those of EBUS-FNA and EUS-FNA alone [7, 8] . Owing to high efficiency and less invasiveness, both endoscopic techniques may become the gold standard in the diagnosis of mediastinal lymphadenopathy, replacing, in many cases, mediastinoscopy in the near future [7] . In spite of that, both endoscopic approaches cannot be used for therapeutic lymphadenectomy. Because EBUS-FNA and EUS-FNA were introduced in our hospital in 2009, they were not used in the diagnosis of mediastinal node staging in the patients of this study. According to the recent European Society of Thoracic Surgeons' guidelines, mediastinoscopy remains the gold standard for the staging of mediastinal lymph nodes, despite its invasiveness requiring general anesthesia [3] . Since the clinical use of the videomediastinoscope, some studies reported that VAMLA was superior to conventional mediastinoscopy for mediastinal nodal staging in lung cancer patients [2, 4, 5] . The sensitivity of mediastinoscopy is mainly influenced by the amount of resected lymph node tissue and the number of investigated lymph node stations [2] . The number of resected lymph nodes by VAMLA was doubled compared with conventional mediastinoscopy [4] . The accuracy of mediastinal staging by VAMLA is comparable to that by open lymphadenectomy [2, 5] . In our experience, a mean number of 16.0 mediastinal nodes and a mean number of 3.5 nodal stations was gained with VAMLA, and, there were no false negative results with lymph node staging. We could also exclude clinically suspicious contralateral N3 mediastinal involvement in eight patients.
The short-and long-term outcome after VATS lobectomy for lung cancer has been frequently reported to be equal or better than after open surgery [9] [10] [11] . However, mediastinal dissection with VATS lobectomy was poorly documented and not always performed [5] . Witte et al. reported that both the number of resected mediastinal node stations and the amounts of the mediastinal specimen in the combined VAMLA and VATS resection group were significantly more than those in VATS only resection group in early lung cancer [12] . During combined or staged operations, we could not find residual lymph nodes in stations 2R, 4R, 4L, and 7. Therefore, we consider that VAMLA is a good complement to VATS lobectomy, especially to leftsided VATS lobectomy, for improving the radicality of mediastinal lymph node dissection in resectable lung cancer. On the left side, complete dissection of the nodes 2 and 4 requires the division of the ligamentum arteriosus Botalli and is not routinely performed [5] .
During the past decade, VAMLA has been shown to be feasible, safe, and effective in the nodal assessment of the mediastinum [2, [4] [5] [6] . However, there are potential complications, such as injury to major vessels, tracheobronchial trees and esophagus, pneumothorax, chylothorax, and recurrent laryngeal nerve palsy with VAMLA. We experienced only one complication of recurrent nerve palsy after VAMLA. For avoiding this complication in VAMLA, visual identification of the left recurrent nerve, systematic sampling instead of en bloc resection of the stations 2L and 4L, and the use of clips for hemostasis instead of electrocautery, are recommended [5] .
In conclusion, VAMLA is a clinically feasible procedure with an acceptable complication rate. It provides a highly accurate staging of mediastinal node in lung cancer patients without false negative results. It may be also an excellent supplementary technique used for complete mediastinal node dissection at minimal invasive cancer surgery, especially with left-sided VATS lobectomy.
